A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to ...

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot ...

NEW YORK, April 30 ― A US judge yesterday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their... Blood thinners Eliquis from ...

Johnson & Johnson (NYSE:JNJ) and Bristol Myers Squibb (NYSE:BMY) have become the latest industry participants to lose legal challenges against the Medicare drug price negotiation program, a major ...

This Monday, there was a pivotal ruling from the U.S., which carries significant implications for the pharmaceutical industry and healthcare costs. 🔍 Case Summary: The court rejected a legal ...

A federal judge has dismissed legal challenges to the Medicare negotiation program brought by Bristol Myers Squibb and Johnson & Johnson, ruling that their claims of unconstitutionality are unfounded.

Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about ...

Bristol Myers Squibb’s product Eliquis was named among the first 10 drugs eligible for Medicare negotiation, as were Xarelto, Imbruvica and Stelara from Johnson & Johnson.